Drug Profile
FCP 3P1
Alternative Names: CardioRexLatest Information Update: 29 May 2001
Price :
$50
*
At a glance
- Originator Forbes Medi-Tech
- Class Antihyperlipidaemics; Phytostanols
- Mechanism of Action Cholesterol absorption inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hypercholesterolaemia
Most Recent Events
- 29 May 2001 Discontinued-II for Hypercholesterolaemia in USA (PO)
- 04 Apr 2000 Phase-II clinical trials for Hypercholesterolaemia in USA (PO)